Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 08 June, 2012 and appeared in  DietType 2 DiabetesPathologyIssue 629

High Fructose Consumption Impairs Liver Function

Obese patients with type 2 diabetes who increased their habitual dietary fructose consumption experienced reduced hepatic adenosine triphosphate concentrations.... 

Advertisement

According to data from an observational, cross-sectional study of the NIH-sponsored Look Ahead Fatty Liver Ancillary Study, obese patients with type 2 diabetes who increased their habitual dietary fructose consumption experienced reduced hepatic adenosine triphosphate concentrations compared with those who consumed less,

The researchers wrote, "These data support our hypothesis that increased dietary fructose consumption may impair hepatocellular energy homeostasis and thus could be a risk factor for progressive liver injury. Further, hyperuricemia may serve as a surrogate marker of hepatic [adenosine triphosphate] depletion following exposure to fructose in patients with [insulin resistance], and potentially [nonalcoholic fatty liver disease]."

Manal F. Abdelmalek, MD, MPH, an associate professor of medicine in the division of gastroenterology at Duke University Medical Center, and colleagues evaluated 244 adults with type 2 diabetes aged 45 to 76 years who were eligible to participate in the study at Johns Hopkins University.

Patients underwent a 130-item food frequency questionnaire to estimate their dietary fructose consumption; researchers also collected uric acid (UA) levels and measured hepatic adenosine triphosphate (ATP) using phosphorus magnetic resonance spectroscopy. A subcategory of patients (n=25) underwent an IV fructose challenge test, the researchers wrote.

Data from the study showed high dietary fructose consumers had "slightly lower baseline hepatic ATP levels and a greater absolute change in hepatic alpha-ATP/Pi ratio (0.08 vs. 0.03, P=.05) and gamma-ATP/Pi ratio, following an intravenous fructose challenge (0.03 vs. 0.06, P=.06). Additionally, patients with high UA levels (≥5.5 mg/dL) showed a lower minimum liver ATP/Pi ratio after the intravenous fructose challenge (4.5 vs. 7, P=.04)," the researchers wrote.

From the results, it was concluded that, impaired hepatic energy homeostasis marks an urgent need for increased public awareness of risks related to high fructose consumption.

Hepatology, May 2012, DOI: 10.1002/hep.25741 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 08 June, 2012 and appeared in  DietType 2 DiabetesPathologyIssue 629

Past five issues: Diabetes Clinical Mastery Series Issue 141 | Issue 681 | Diabetes Clinical Mastery Series Issue 140 | Issue 680 | Diabetes Clinical Mastery Series Issue 139 |

2013 Most Popular Articles:

Mortality Risk in Patients with Type 2 Diabetes
Posted May 23, 2013
Bacteria in the Gut Improves the Management of Obesity and Type 2 Diabetes
Posted May 23, 2013
Hypoglycemia Treatment and Prevention Related to Physical Activity
Posted May 31, 2013
Scientist Use Bone Marrow Stem Cells to Cure Type 1 Diabetes
Posted June 06, 2013
Simvastatin Can Reduce the Benefits of Exercise in Active Adults
Posted May 23, 2013
Diabetes Epidemic Growing
Posted May 23, 2013
Co-Q10 May Offset Risk of Diabetes with Statin Use
Posted May 23, 2013
Artificial Sweeteners May Affect Blood Glucose Levels and Insulin Response
Posted June 06, 2013
FDA Advisory Panel Votes to Remove Avandia's Highly Restrictive Label
Posted June 06, 2013
Frequency of Blood Glucose Testing in Type 1's: How Often is Enough?
Posted June 13, 2013

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
Cast Your Vote
If the FDA relaxes prescribing restrictions on Avandia, will you recommend it?

Navigate Diabetes In Control



Search Articles On Diabetes In Control